(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.18%) $78.24
(0.32%) $2.21
(-0.04%) $2 323.20
(-0.12%) $27.51
(0.28%) $991.20
(0.07%) $0.930
(0.22%) $10.92
(0.09%) $0.800
(0.02%) $91.46
Quarter results tomorrow
(bmo 2024-05-09)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally...
Stats | |
---|---|
Today's Volume | 65 400.00 |
Average Volume | 365 936 |
Market Cap | 121.74B |
EPS | ¥0 ( 2024-02-14 ) |
Next earnings date | ( ¥14.90 ) 2024-05-09 |
Last Dividend | ¥42.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 77.59 |
ATR14 | ¥0.445 (0.04%) |
Volume Correlation
Takara Bio Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Takara Bio Inc. Correlation - Currency/Commodity
Takara Bio Inc. Financials
Annual | 2022 |
Revenue: | ¥78.14B |
Gross Profit: | ¥44.77B (57.29 %) |
EPS: | ¥132.97 |
FY | 2022 |
Revenue: | ¥78.14B |
Gross Profit: | ¥44.77B (57.29 %) |
EPS: | ¥132.97 |
FY | 2022 |
Revenue: | ¥67.70B |
Gross Profit: | ¥49.21B (72.69 %) |
EPS: | ¥164.84 |
FY | 2021 |
Revenue: | ¥46.09B |
Gross Profit: | ¥31.87B (69.16 %) |
EPS: | ¥79.29 |
Financial Reports:
No articles found.
Takara Bio Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥0 (N/A) |
¥0 (N/A) |
¥42.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥1.000 | 2012-03-28 |
Last Dividend | ¥42.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 13 | -- |
Total Paid Out | ¥114.10 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.77 | -- |
Div. Sustainability Score | 8.16 | |
Div.Growth Potential Score | 6.07 | |
Div. Directional Score | 7.12 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7942.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7172.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
6413.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
5384.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4401.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3569.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2804.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
1414.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
9708.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
8725.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0330 | 1.500 | 9.34 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0128 | 1.200 | 9.57 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0141 | 1.500 | -0.954 | -1.431 | [0.1 - 1] |
payoutRatioTTM | 3.21 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 7.45 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 5.46 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.25 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 61.42 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 200.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 81.73 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.553 | 1.000 | 4.11 | 4.11 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0309 | 1.000 | -1.382 | -1.382 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0.387 | 0.800 | -0.751 | -0.601 | [0.5 - 2] |
Total Score | 8.16 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 77.42 | 1.000 | 2.28 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0141 | 2.50 | -0.613 | -1.431 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 81.73 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 1.683 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 200.29 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 3.21 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0.717 | 1.500 | 8.55 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.506 | 1.000 | 10.00 | 0 | [0.1 - 0.5] |
Total Score | 6.07 |
Takara Bio Inc.
Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators